Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Regeneron Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

May 26, 2023, 6:21 p.m.

REGN
/zigman2/quotes/203149337/composite

$

724.95

Change

-0.10 -0.01%

Volume

Volume 44,576

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Previous close

$ 725.00

$ 725.05

Change

+0.05 +0.0069%

Day low

Day high

$719.00

$726.77

Open

52 week low

52 week high

$538.01

$837.55

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accel...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Valuation

P/E Current

19.58

P/E Ratio (with extraordinary items)

20.40

P/E Ratio (without extraordinary items)

18.88

Price to Sales Ratio

6.73

Price to Book Ratio

3.49

Price to Cash Flow Ratio

16.33

Enterprise Value to EBITDA

13.94

Enterprise Value to Sales

6.23

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

1,027,162.00

Income Per Employee

366,079.00

Receivables Turnover

2.14

Total Asset Turnover

0.45

Liquidity

Current Ratio

5.06

Quick Ratio

4.29

Cash Ratio

2.46

Profitability

Gross Margin

84.38

Operating Margin

42.63

Pretax Margin

39.91

Net Margin

35.64

Return on Assets

15.86

Return on Equity

20.94

Return on Total Capital

22.16

Return on Invested Capital

18.82

Capital Structure

Total Debt to Total Equity

11.92

Total Debt to Total Capital

10.65

Total Debt to Total Assets

9.23

Long-Term Debt to Equity

11.92

Long-Term Debt to Total Capital

10.65

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 68 1988 Co-President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 57 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/01/2023 Arthur Frederick Ryan
Director 		15   Disposition at $808.11 per share. 12,121
05/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $807.5 per share. 13,727
05/01/2023 Arthur Frederick Ryan
Director 		15   Disposition at $806.53 per share. 12,097
05/01/2023 Arthur Frederick Ryan
Director 		5   Disposition at $805.34 per share. 4,026
05/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $804.51 per share. 1,609
05/01/2023 Arthur Frederick Ryan
Director 		30   Disposition at $803.58 per share. 24,107
05/01/2023 Arthur Frederick Ryan
Director 		16   Disposition at $802.67 per share. 12,842
04/03/2023 P. Roy Vagelos
Director 		259   Gift at $0 per share. 0
04/03/2023 Marion McCourt
EVP Commercial 		1,100   Disposition at $818.8 per share. 900,680
04/03/2023 Arthur Frederick Ryan
Director 		6   Disposition at $823.34 per share. 4,940
04/03/2023 Arthur Frederick Ryan
Director 		9   Disposition at $822.37 per share. 7,401
04/03/2023 Arthur Frederick Ryan
Director 		1   Disposition at $821.61 per share. 821
04/03/2023 Arthur Frederick Ryan
Director 		5   Disposition at $820.55 per share. 4,102
04/03/2023 Arthur Frederick Ryan
Director 		32   Disposition at $819.48 per share. 26,223
04/03/2023 Arthur Frederick Ryan
Director 		27   Disposition at $818.47 per share. 22,098
04/03/2023 Arthur Frederick Ryan
Director 		13   Disposition at $817.49 per share. 10,627
04/03/2023 Arthur Frederick Ryan
Director 		7   Disposition at $816.58 per share. 5,716
04/03/2023 Marion McCourt
EVP Commercial 		1,100   Derivative/Non-derivative trans. at $372.46 per share. 409,706
03/28/2023 Robert E. Landry
EVP Finance CFO 		31   Disposition at $826.36 per share. 25,617
03/28/2023 Robert E. Landry
EVP Finance CFO 		243   Disposition at $825.37 per share. 200,564
03/28/2023 Robert E. Landry
EVP Finance CFO 		157   Disposition at $824.54 per share. 129,452
03/28/2023 Robert E. Landry
EVP Finance CFO 		181   Disposition at $823.6 per share. 149,071
03/28/2023 Robert E. Landry
EVP Finance CFO 		128   Disposition at $822.67 per share. 105,301
03/28/2023 Robert E. Landry
EVP Finance CFO 		142   Disposition at $821.4 per share. 116,638
03/28/2023 Robert E. Landry
EVP Finance CFO 		115   Disposition at $820.85 per share. 94,397
03/28/2023 Robert E. Landry
EVP Finance CFO 		10   Disposition at $818.81 per share. 8,188
03/27/2023 Robert E. Landry
EVP Finance CFO 		7   Disposition at $830.01 per share. 5,810
03/27/2023 Robert E. Landry
EVP Finance CFO 		4   Disposition at $829.16 per share. 3,316
03/27/2023 Robert E. Landry
EVP Finance CFO 		13   Disposition at $825.59 per share. 10,732
03/27/2023 Robert E. Landry
EVP Finance CFO 		4   Disposition at $824.3 per share. 3,297
03/27/2023 Robert E. Landry
EVP Finance CFO 		18   Disposition at $822.57 per share. 14,806
03/27/2023 Robert E. Landry
EVP Finance CFO 		48   Disposition at $821.39 per share. 39,426
03/27/2023 Robert E. Landry
EVP Finance CFO 		50   Disposition at $820.46 per share. 41,023
03/27/2023 Robert E. Landry
EVP Finance CFO 		39   Disposition at $819.47 per share. 31,959
03/27/2023 Robert E. Landry
EVP Finance CFO 		2,204   Derivative/Non-derivative trans. at $825.17 per share. 1,818,674
03/27/2023 Robert E. Landry
EVP Finance CFO 		589   Derivative/Non-derivative trans. at $825.17 per share. 486,025
03/27/2023 Robert E. Landry
EVP Finance CFO 		3,000   Derivative/Non-derivative trans. at $378.98 per share. 1,136,940
03/27/2023 Robert E. Landry
EVP Finance CFO 		800   Derivative/Non-derivative trans. at $381.92 per share. 305,536
03/24/2023 Bonnie L. Bassler
Director 		1,240   Disposition at $818 per share. 1,014,320
03/24/2023 Bonnie L. Bassler
Director 		1,240   Derivative/Non-derivative trans. at $380.95 per share. 472,378
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		400   Disposition at $810.3 per share. 324,120
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		700   Disposition at $806.47 per share. 564,529
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		47   Disposition at $805.55 per share. 37,860
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		254   Disposition at $804.38 per share. 204,312
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		642   Disposition at $803.3 per share. 515,718
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		1,237   Disposition at $802.54 per share. 992,741
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		122   Disposition at $801.16 per share. 97,741
03/23/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		254   Disposition at $800.59 per share. 203,349
03/23/2023 Christopher Robert Fenimore
SVP Controller 		2,192   Disposition at $806.47 per share. 1,767,782
03/23/2023 P. Roy Vagelos
Director 		25,000   Gift at $0 per share. 0
03/23/2023 Joseph J. LaRosa
EVP General Counsel and Secret 		6,742   Derivative/Non-derivative trans. at $801.59 per share. 5,404,319
03/23/2023 Joseph J. LaRosa
EVP General Counsel and Secret 		10,000   Derivative/Non-derivative trans. at $270.43 per share. 2,704,300
03/10/2023 Joseph J. LaRosa
EVP General Counsel and Secret 		1,006   Gift at $0 per share. 0
03/01/2023 Marion McCourt
EVP Commercial 		1,100   Disposition at $759.89 per share. 835,879
03/01/2023 Arthur Frederick Ryan
Director 		7   Disposition at $766.32 per share. 5,364
03/01/2023 Arthur Frederick Ryan
Director 		10   Disposition at $765.55 per share. 7,655
03/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $764.49 per share. 12,996
03/01/2023 Arthur Frederick Ryan
Director 		11   Disposition at $763.51 per share. 8,398
03/01/2023 Arthur Frederick Ryan
Director 		9   Disposition at $762.28 per share. 6,860
03/01/2023 Arthur Frederick Ryan
Director 		16   Disposition at $761.62 per share. 12,185
03/01/2023 Arthur Frederick Ryan
Director 		10   Disposition at $760.54 per share. 7,605
03/01/2023 Arthur Frederick Ryan
Director 		15   Disposition at $759.48 per share. 11,392
03/01/2023 Arthur Frederick Ryan
Director 		5   Disposition at $758.2 per share. 3,791
03/01/2023 Marion McCourt
EVP Commercial 		1,100   Derivative/Non-derivative trans. at $372.46 per share. 409,706
02/22/2023 P. Roy Vagelos
Director 		29,005   Derivative/Non-derivative trans. at $750.16 per share. 21,758,390
02/22/2023 P. Roy Vagelos
Director 		42,500   Derivative/Non-derivative trans. at $270.43 per share. 11,493,275
02/12/2023 Marion McCourt
EVP Commercial 		1,276   Derivative/Non-derivative trans. at $751.78 per share. 959,271
/news/latest/company/us/regn

MarketWatch News on REGN

  2. Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market

    5:21 p.m. May 25, 2023

    - MarketWatch Automation

  3. Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market

    5:21 p.m. May 24, 2023

    - MarketWatch Automation

  5. Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market

    5:20 p.m. May 22, 2023

    - MarketWatch Automation

  9. Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market

    5:21 p.m. May 16, 2023

    - MarketWatch Automation

  13. Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market

    5:21 p.m. May 10, 2023

    - MarketWatch Automation

  15. Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market

    5:22 p.m. May 8, 2023

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. Sanofi Wins Supreme Court Patent Dispute With Amgen

    2:33 a.m. May 19, 2023

    - The Wall Street Journal Interactive Edition

  2. For Tax Executives, More Disclosure on Global Liabilities Means More Headaches

    5:30 a.m. May 17, 2023

    - The Wall Street Journal Interactive Edition

  3. FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics

    2:34 a.m. May 17, 2023

    - The Wall Street Journal Interactive Edition

  4. CEO Pay Packages Fell Sharply in 2022, the First Decline in a Decade

    2:36 a.m. May 16, 2023

    - The Wall Street Journal Interactive Edition

  5. 10-Q: REGENERON PHARMACEUTICALS, INC.

    7:18 a.m. May 4, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  6. Amgen Seeks to Monopolize Nature

    5:53 p.m. March 26, 2023

    - The Wall Street Journal Interactive Edition

  7. Regeneron, Sanofi Look for Billions From COPD Drug

    2:33 a.m. March 27, 2023

    - The Wall Street Journal Interactive Edition

  8. Regeneron Borrows From Big Pharma Playbook

    2:33 a.m. March 13, 2023

    - The Wall Street Journal Interactive Edition

  9. LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter

    9:00 a.m. Feb. 12, 2023

    - GuruFocus.com

  11. Freedom Day Solutions, LLC Buys 3, Sells 2 in 4th Quarter

    11:00 a.m. Feb. 8, 2023

    - GuruFocus.com

  12. Top 5 4th Quarter Trades of MCDONALD CAPITAL INVESTORS INC/CA

    7:00 p.m. Feb. 7, 2023

    - GuruFocus.com

  13. Top 5 4th Quarter Trades of Pacer Advisors, Inc.

    7:00 p.m. Feb. 6, 2023

    - GuruFocus.com

  15. Top 5 4th Quarter Trades of Tom Gayner

    11:00 p.m. Feb. 3, 2023

    - GuruFocus.com

  16. SEIZERT CAPITAL PARTNERS, LLC Buys 3, Sells 2 in 4th Quarter

    7:00 p.m. Jan. 30, 2023

    - GuruFocus.com

  17. Covenant Asset Management, LLC Buys 3, Sells 2 in 4th Quarter

    7:00 p.m. Jan. 24, 2023

    - GuruFocus.com

  19. Old Port Advisors Buys 3, Sells 2 in 4th Quarter

    3:00 p.m. Jan. 11, 2023

    - GuruFocus.com

  20. Nasdaq Rises, as Dow and S&P 500 Slip

    4:12 a.m. Jan. 10, 2023

    - The Wall Street Journal Interactive Edition

  21. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$12.17B

Net Income

$4.34B

Employees

11,851

Annual Report for REGN

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. Regeneron Announces Investor Conference Presentations

    4:01 p.m. May 18, 2023

    - GlobeNewswire

Link to MarketWatch's Slice.